Poland· PL-100139456
Suboxone
A buprenorphin, kombinationen product containing buprenorphini hydrochloridum + naloxoni hydrochloridum dihydricum, registered in Poland by Indivior Europe Limited. The same ATC class is registered in 10 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Buprenorphin, kombinationen is registered in 10 of 19 countries.
Countries holding a registration under ATC N07BC51 (buprenorphin, kombinationen), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 6 of them publish a price we can compare per daily dose
Buprenorphin, kombinationen · ATC N07BC51
10 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
The record
At a glance
URPL (Poland)- Active substance
- Buprenorphini hydrochloridum + Naloxoni hydrochloridum dihydricum
- Manufacturer
- Indivior Europe Limited
- Country
- Poland (PL)
- ATC code
- N07BC51
- ATC class
- Buprenorphin, Kombinationen
- Defined daily dose
- 8 mg, SL
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 5
- gtin05909990043101
- gtin05909990043125
- gtin05000158070790
- gtin05054792000019
- gtin05054792002174
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under N07BC51
Buprenorphin, kombinationen, as other registers publish it.
- IrelandBulexin 2 mg/0.5 mg sublingual tabletsPinewood Laboratories Limited
- IrelandBulexin 4 mg/1 mg sublingual tabletsPinewood Laboratories Limited
- IrelandBulexin 8 mg/2 mg sublingual tabletsPinewood Laboratories Limited
- DenmarkBunalictSandoz A/S
- FinlandBunalictSandoz A/S
- FinlandBunalictSandoz A/S
- NorwayBunalictSandoz - København
- DenmarkBunalictSandoz A/S
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4afbf03e-0d2b-4267-bb05-151051aaa047 GET /v1/drugs/4afbf03e-0d2b-4267-bb05-151051aaa047?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki podjęzykowe",
"source": "urpl",
"strength": "8 mg + 2 mg",
"packaging": "05909990043101 ¦ Rpw ¦ Skasowane ¦ EU/1/06/359/003 ¦ 35524\n7 tabl.\n05909990043125 ¦ Rpw ¦ Skasowane ¦ EU/1/06/359/004 ¦ 35525\n28 tabl.\n05000158070790 ¦ Rpw ¦ Skasowane ¦ EU/1/06/359/003 ¦ 111028\n7 tabl.\n05054792000019 ¦ Rpw ¦ EU/1/06/359/004 ¦ 111029\n28 tabl.\n05054792002174 ¦ Rpw ¦ EU/1/06/359/003 ¦ 134884\n7 tabl.",
"substance": "Buprenorphini hydrochloridum 8 mg + Naloxoni hydrochloridum dihydricum 2 mg",
"common_name": "Buprenorphini hydrochloridum + Naloxoni hydrochloridum dihydricum",
"pl_product_id": "100139456",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about buprenorphin, kombinationen.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.